Nanotherapeutics

ByPrashant Verma

Ch-9280

Overview

Nanotherapeutics overcomes the problems offered by the traditional drugs such as:

Gastro-Instentinal Side effects Providing a means to use non-invasive routes of

administration rather than injection. Enhancing the systemic absorption of insoluble

compounds and macromolecules. Improving the consistency of absorption. Reducing the amount of dose required and

potentially the frequency of dosing.

Products

Some of the products developed in the field of Nanotherapeutics:-

NanoDry NanoCoat NanoQuad

NanoDry

It is a process of rapid drying technique that produces particles on the nanometer to micrometer scale for efficient and reproducible delivery of large and small molecule.

NanoCOAT

The NanoCOAT™ process is a patented solventless-microencapsulation system for coating micron and sub-micron size powders. A core nanoparticle/microparticle is encapsulated with a thin layer of a coating material, such as a surfactant or a biodegradable polymer. The coating may be applied to slow the rate of release of an active component, improve the dispersion/flow properties into the lung or nasal cavity, or increase the absorption into systemic circulation.

NanoQuad

NanoQuad can be used in various processes, using the NanoQUAD® process offers a safe and efficient way to manufacture formulations that:

Exhibit rapid dissolution rates Provide increased oral bioavailability Deliver more rapid absorption of active drug

substances Minimizing fed-fasted effects

Applications of Nanotherapeutics

Nanotherapeutics can be applied in 4 different ways: Oral Inhalation/Nasal Injectible Topical

Potential Uses So far

Novel Nanotherapeutic Delivers Clot-Busting Drugs Directly to Obstructed Blood Vessels

Nanotherapeutics’ and NCI Researchers Co-Author Publication Showing Promise with New Oral Nanoparticle HIV Vaccine

References

Google.com http://www.nanotherapeutics.com/nanotechnology.p

hp http://www.sciencedaily.com/releases/2012/07/1207

05181246.htm http://www.prweb.com/releases/2012/8/prweb97750

09.htm